Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Income Before Tax

Profit after all operating and non-operating items but before income tax.

Nektar TherapeuticsNASDAQ: NKTR

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$40.3M, compared with -$41.78M a year earlier. Trailing-twelve-month income before tax was -$156.74M.

Context

  • Income before tax amounted to 297.3% of revenue in FY2025, up 176.2 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$40.3M or moves back toward the trailing-twelve-month quarterly average of -$39.19M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$40.3M+10.1% QoQ
Last fiscal yearDec 2025
-$164.21M-37.8% YoY
LTMJun 2026
-$156.74M-27.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.5%——
1 year-37.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(164.21M) USD
Year-over-year change
-37.8%

Income Before Tax vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.8% is the 6th highest of 10, against a peer median of -6.7%.
  • Income before tax amounts to 287.1% of revenue for NKTR, versus a peer median of 368.3%.
NKTR Competitors
Income Before Tax for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M USD-6.7%——
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
ANLAdlai Nortye Ltd.LTM Jun 2024-$53.42M USD——823.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M USD-29.5%—45.2%
NKTRNektar TherapeuticsLTM Jun 2026-$156.74M USD-27.8%—287.1%
XNCRXencor, Inc.LTM Jun 2026-$160.85M USD+10.3%—153.2%
CHRSCoherus Oncology, Inc.LTM Mar 2026-$172.66M USD-41.8%—368.3%
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M USD-47.7%—386.3%
Peer median (excluding NKTR) —-6.7%—368.3%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.